Abstract
Cytochrome P450s (CYPs) are responsible for the metabolism of a majority of marketed drugs and, as a consequence, alteration in CYP activity can result in clinically relevant drug-drug interactions (DDIs). Drugs that are time dependent inhibitors (TDIs) of CYPs have been reported to cause severe DDIs, leading to prescription adjustments and, in certain cases, have been withdrawn from the market (Zhou et al., Ther Drug Monit 29:687–710, 2007). Oftentimes, TDI is the result of mechanism-based inactivation (MBI), where CYPs catalyze the formation of reactive metabolites that irreversibly or quasi-irreversibly inhibit its own activity. In order to restore basal CYP activity lost as a result of MBI de novo enzyme synthesis is required, and therefore, MBI can have greater clinical consequences than reversible CYP inhibition. Methodologies capable of identifying MBIs in drug discovery are warranted to address this potential liability. The most commonly employed assay to identify MBIs is by measuring the IC50 for CYP enzymes with and without pre-incubation of discovery compounds with human liver microsomes. An IC50 shift assay for CYP3A will be described in greater detail given the enzyme’s prominent role in drug metabolism and association with severe clinical DDIs resulting from MBI; however, the overall assay design can easily be adopted for other CYPs. While the IC50 shift assay can be used to build SAR to mitigate this liability in discovery, clinical risk assessment of an MBI requires the determination of the kinetic parameters KI and kinact.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zhou SF et al (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29(6):687–710
Silverman R (1998) Mechanisim-based enzyme inactivation: chemistry and enzymology. CRC Press, Boca Raton, FL
Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus. Br J Clin Pharmacol 52(1):107–117
Plant N (2007) The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 1770(3):478–488
Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1):41–57
Mullins ME et al (1998) Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 280(2):157–158
Moyle GJ, Back D (2001) Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2(2):105–113
Obach RS, Walsky RL, Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35(2):246–255
Chauret N, Gauthier A, Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 26(1):1–4
Atkinson A, Kenny JR, Grime K (2005) Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos 33(11):1637–1647
Grime KH et al (2009) Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. Eur J Pharm Sci 36(2–3):175–191
Orr ST et al (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55(11):4896–4933
Acknowledgements
The views expressed here are solely those of the author and do not reflect the opinions of Janssen Research & Development, LLC.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Coe, K.J., Skaptason, J., Koudriakova, T. (2014). Identification of Time-Dependent CYP Inhibitors Using Human Liver Microsomes (HLM). In: Caldwell, G., Yan, Z. (eds) Optimization in Drug Discovery. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-742-6_18
Download citation
DOI: https://doi.org/10.1007/978-1-62703-742-6_18
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-741-9
Online ISBN: 978-1-62703-742-6
eBook Packages: Springer Protocols